Jenny X. Chen, MD

Head and neck surgeon David Eisele specializes in surgery for malignant and benign tumors of the head and neck, with a focus on salivary gland neoplasms and disorders of the salivary glands that can be treated surgically. He is an expert in minimally invasive surgical approaches, including sialendoscopy. Salivary gland neoplasms and disorders are also the focus of Dr. Eisele’s research. He has published more than 300 research papers and edited multiple books related to head and neck surgery. Dr. Eisele earned a medical degree from Cornell University Medical College and completed residency training in general surgery and in otolaryngology–head and neck surgery at the University of Washington. From 2012 to 2025, he served as director of the Department of Otolaryngology–Head and Neck Surgery at the Johns Hopkins University School of Medicine.

Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer.Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research.Specific research projects include:1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103).2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs;3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs.

The Johns Hopkins Outpatient Pharmacy offers a full inventory of standard, specialty and over-the-counter medications, as well as the convenience of discharge medication processing. International patient pharmaceutical services are also available.